Download PDF
Exp Clin Endocrinol Diabetes 2007; 115(5): 292-297
DOI: 10.1055/s-2007-970162
Article

© J. A. Barth Verlag in Georg Thieme Verlag KG · Stuttgart · New York

Long-Term Treatment of Central Cushing's Syndrome with Rosiglitazone

M. Morcos 1 , B. Fohr 1 , J. Tafel 1 , F. Pfisterer 1 , A. Hamann 1 , P. Humpert 1 , H. Bode 2 , V. Schwenger 1 , M. Zeier 1 , C. Becker 1 , C. Kasperk 1 , T. Schilling 1 , H.P. Hammes 2 , A. Bierhaus 1 , P.P. Nawroth 1
  • 1University of Heidelberg, Department of Internal Medicine, Endocrinology, Metabolism and Clinical Chemistry Heidelberg, Germany
  • 2University Hospital Mannheim, Germany
Further Information

Publication History

received 23. 8. 2006 first decision 31. 1. 2007

accepted 31. 1. 2007

Publication Date:
21 May 2007 (online)

Also available at
    Permissions and Reprints

Abstract

Context: Central Cushing's syndrome is not always curable by surgery or radiation of the pituitary. Medical treatment is often not possible or effective. Some studies revealed beneficial effects of the PPARγ (Peroxisome-Proliferator-Activator- Receptor-gamma)-agonist rosiglitazone (RG) in in vitro studies, animal models and short term clinical studies.

Objective: of this study was to observe the long-term effects of RG-treatment on cortisol- and ACTH -secretion, clinical outcomes and morphological changes of the pituitary in patients with persistent ACTH-overproduction despite previous operation and radiation.

Design, setting and patients: 14 patients with persistent central ACTH -production were included and monitored over a period up to 12 months. RG was administered daily and increased to a maximum dosage of 24 mg daily, according to the response of ACTH and cortisol secretion. ACTH and cortisol were measured at least every 4 weeks during RG treatment.

Results: Patients were treated between 4 and 12 months with RG (mean 6.8 months). Compared to baseline, ACTH- and cortisol levels dropped significantly (p<0.01) after 12, 16, 20, 24 and 28 weeks but thereafter rose again during the study period, despite continuous RG- treatment and dose increase up to the maximum dosage. This was paralleled by reocurrence of clinical symptoms. MRI-scans were performed in 6 patients because of persisting visible adenoma, but showed no morphological changes.

Conclusion: RG seems not to be a long-term treatment option for patients with persistent central ACTH-evcess. Though, in order to reduce perioperative complications, short term treatment of patients could be an alternative.

Key words

glucocorticoids - hormones - rosiglitazone - Cushing's disease - pituitary adenoma

References

  • 1 Arnaldi G, Angeli A, Atkinson AB, Bertagna X, Cavagnini F, Chrousos GP, Fava GA, Findling JW, Gaillard RC, Grossman AB, Kola B, Lacroix A, Mancini T, Mantero F, Newell-Price J, Nieman LK, Sonino N, Vance ML, Giustina A, Boscaro M. Diagnosis and complications of Cushing's syndrome: a consensus statement.  J Clin Endocrin Metab. 2003;  88 5593-5602
    CrossrefPubMedGoogle Scholar
  • 2 Bochicchio D, Losa M, Buchfelder M. Factors influencing the immediate and late outcome of Cushing's disease treated by transsphenoidal surgery: a retrospective study by the European Cushing's Disease Survey Group.  J Clin Endocrinol Metab. 1995;  80 3114-3120
    CrossrefPubMedGoogle Scholar
  • 3 Invitti C, Pecori Giraldi F, De Martin M. Cavagnini F and the Study roup of the Italian Society of Endocrinology on the Pathophysiologyof the Hypothalamic-Pituitary-Adrenal Axis. Diagnosis and management of Cushing's syndrome: results of an Italian multicentre study.  J Clin Endocrinol Metab. 1999;  84 440-448
    CrossrefPubMedGoogle Scholar
  • 4 Pereira AM, van Aken MO, van Dulken H, Schutte PJ, Biermasz NR, Smit JW, Roelfsema F, Romijn JA. Long-term predictive value of postsurgicalcortisol concentrations for cure and risk of recurrence in Cushing's disease.  J Clin Endocrinol Metab. 2003;  88 5858-5864
    CrossrefPubMedGoogle Scholar
  • 5 Mampalam TJ, Tyrrell JB, Wilson CB. Transsphenoidal microsurgery for Cushing disease. A report of 216 cases.  Ann Intern Med. 1988;  109 ((6)) 487-493
    PubMedGoogle Scholar
  • 6 Estrada J, Boronat M, Mielgo M, Magallon R, Millan I, Diez S, Lucas T, Barcelo B. The longterm outcome of pituitary irradiation after unsuccessful transsphenoidal surgery in Cushing's disease.  N Engl J Med. 1997;  336 172-177
    CrossrefPubMedGoogle Scholar
  • 7 Miller JW, Crapo L. The medical treatment of Cushing's syndrome.  Endocr Rev. 1993;  14 ((4)) 443-458
    CrossrefPubMedGoogle Scholar
  • 8 Nieman LK. Medical therapy of Cushing's disease.  Pituitary. 2002;  5 77-82
    CrossrefPubMedGoogle Scholar
  • 9 Lirieger DT, Amorosa L, Linick F. Cyproheptadine-induced remission of Cushing's disease.  N Engl J Med. 1975;  293 ((18)) 893-896
    PubMedGoogle Scholar
  • 10 Sonino N. The use of ketoconazole as an inhibitor of steroid production.  N Engl J Med. 1987;  317 ((13)) 812-818
    PubMedGoogle Scholar
  • 11 Trainer PJ, Besser M. Cushing's syndrome. Therapy directed at the adrenal glands.  Endocrinol Metab Clin North Am. 1994;  23 ((3)) 571-584
    PubMedGoogle Scholar
  • 12 Heaney AP, Fernando M, Yong WH, Melmed S. Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas.  Nat Med. 2002;  8 ((11)) 1281-1287
    PubMedGoogle Scholar
  • 13 K Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, Evans RM. 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma.  Cell. 1995;  83 ((5)) 803-812
    CrossrefPubMedGoogle Scholar
  • 14 Goldstein BJ. Rosiglitazone.  Int J Clin Pract. 2000;  54 333-337
    PubMedGoogle Scholar
  • 15 Kliewer SA, Lenhard JM, Willson TM, Patel I, Morris DC, Lehmann JM. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation.  Cell. 1995;  83 ((5)) 813-819
    CrossrefPubMedGoogle Scholar
  • 16 Spiegelman BM. PPAR-gamma: adipogenic regulator and thiazolidine receptor.  Diabetes. 1998;  47 507-514
    CrossrefPubMedGoogle Scholar
  • 17 Saltiel AR, Olefsky JM. Thizolidindiones in the treatment of insulin resistance and type II diabetes.  Diabetes. 1996;  45 1661-1669
    CrossrefPubMedGoogle Scholar
  • 18 Stumvoll M, Haring HU. Glitazones: clinical effects and molecular mechanisms.  Ann Med. 2002;  34 ((3)) 217-224
    PubMedGoogle Scholar
  • 19 Bosco AA, Lerario AC, Santos RF, Wajchenberg BL. Effect of thalidomide and rosiglitazone on the prevention of diabetic retinopathy in streptozotocin-induced diabetic rats.  Diabetologia. 2003;  46 ((12)) 1669-1675
    CrossrefPubMedGoogle Scholar
  • 20 Panigrahy D, Singer S, Shen LQ, Butterfield CE, Freedman DA, Chen EJ, Moses MA, Kilroy S, Duensing S, Fletcher C, Fletcher JA, Hlatky L, Hahnfeldt P, Folkman J, Kaipainen A. PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis.  J Clin Invest. 2002;  110 ((7)) 923-932
    CrossrefPubMedGoogle Scholar
  • 21 Xin X, Yang S, Kowalski J, Gerritsen ME. Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo.  J Biol Chem. 1999;  274 ((13)) 9116-9121
    CrossrefPubMedGoogle Scholar
  • 22 Elstner E, Muller C, Koshizuka K, Williamson EA, Park D, Asou H, Shintaku P, Said JW, Heber D, Koeffler HP. Ligands for peroxisome proliferator-activated receptor-γ and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice.  Proc Natl Acad Sci. 1998;  95 ((15)) 8806-8811
    CrossrefPubMedGoogle Scholar
  • 23 Kubota T, Koshizuka K, Williamson EA, Asou H, Said JW, Holden S, Miyoshi I, Koeffler HP. Ligand for peroxisome proliferator-activated receptor- (troglitazone) has potent anti-tumor effects against prostate cancer both in vitro and in vivo.  Cancer Ressearch. 1998;  58 3344-3352
    PubMedGoogle Scholar
  • 24 Sarraf P, Mueller E, Jones D, King FJ, DeAngelo DJ, Partridge JB, Holden SA, Chen LB, Singer S, Fletcher C, Spiegelman BM. Differentiation and reversal of malignant changes in colon cancer through PPARgamma.  Nat Med. 1998;  4 ((9)) 1046-1052
    PubMedGoogle Scholar
  • 25 Theocharisa S, Margeli A, Kouraklis G. Peroxisome proliferator activated receptor-gamma ligands as potent antineoplastic agents.  Curr Med Chem Anti-Canc Agents. 2003;  3 239-251
    PubMedGoogle Scholar
  • 26 Heaney AP, Fernando MH, Melmed S. PPARγ receptor ligands: a novel therapy for pituitary tumors.  J Clin Invest. 2003;  111 1381-1388
    CrossrefPubMedGoogle Scholar
  • 27 Sonino N, Boscaro M, Fallo F. Pharmacologic management of Cushings syndrome: new targets for therapy.  Treat Endocrinol. 2005;  4 ((2)) 87-94
    CrossrefPubMedGoogle Scholar
  • 28 Alevizaki M, Philippou G, Zapanti L, Alevizaki CC, Anastasiou E, Mavrikakis M. Significant improvement of recurrent pituitary-dependent Cushing's syndrome after administration of a PPAR-γ agonist. Program of the 86th Annual Meeting of the Endocrine Society. New Orleans LA 2004 p 418 (Abstract)
    Google Scholar
  • 29 Ambrosi B, Arosio M, Dall'Asta C, Cannavo S, Libe R, Vigo T, Chiodini I, Epaminonda P, Trimarchi F, Beck-Peccoz P. Effects of chronic administration of the PPAR-y receptor ligand rosiglitazone in Cushing's disease.  Eur J Endocrinol. 2004;  151 173-178
    CrossrefPubMedGoogle Scholar
  • 30 Cannavo S, Ambrosi B, Chiodini I, Vigo T, Russo A, Milici C, Barbetta L, Dall'Asta C, Adda G, Arosio M. Baseline and CRHstimulated ACTH and cortisol levels after administration of the PPAR-g ligand, rosiglitazone, in Cushing's disease.  J End Invest. 2004;  2994 ((27)) 8-11
    PubMedGoogle Scholar
  • 31 Heaney AP, Drange MR, Melmed S. Functional PPAR-γ receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas (Cushing's disease).  The Endocrine Society's 85th Annual Meeting. 2003;  , 19-22 June, (Abstract)
    PubMedGoogle Scholar
  • 32 Hull SSA, Sheridan B, Atkinson AB. Pre-operative medical therapy with rosiglitazone in two patients with newly diagnosed pituitary-dependent Cushing's syndrome.  Clinical Endocrinology. 2005;  62 258-262
    PubMedGoogle Scholar
  • 33 Mullan KR, Leslie H, McCnace DR, Sheridan B, Atkinson AB. The PPAR-gamma activator rosiglitazone fails to lower plasma ACTH levels in patients with Nelson's syndrome.  Clin Endocrinol. 2006;  64 ((5)) 519-522
    CrossrefPubMedGoogle Scholar
  • 34 Li AC, Brown KK, Silvestre MJ, Willson TM, Palinski W, Glass CK. Peroxisome proliferatoractivated receptor gamma ligands inhibit development of atherosclerosis in LDL receptordeficient mice.  J Clin Invest. 2000;  106 ((4)) 523-531
    CrossrefPubMedGoogle Scholar
  • 35 Ohta K, Endo T, Haraguchi K, Hershman JM, Onaya T. Ligands for peroxisome proliferatoractivated receptor gamma inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells.  J Clin Endocrinol Metab. 2001;  86 ((5)) 2170-2177
    CrossrefPubMedGoogle Scholar
  • 36 Veldhuis JD, Zhang G, Garmey JC. Troglitazone, an insulin-sensitizing thiazoledinedione, represses combined stimulation by LH and insulin of de novo androgen biosynthesis by thecal cells in vitro.  J Clin Endocrin Metab. 2002;  87 1129-1133
    PubMedGoogle Scholar
  • 37 Arlt W, Auchus RJ, Miller WL. Thiazoledinediones but not metformin directly inhibit the steroidogenic enzymes P450c17 and 3b-hydroxysteroid dehydrogenase.  J Biol Chem. 2001;  276 16767-16771
    CrossrefPubMedGoogle Scholar
  • 38 Willi SM, Kennedy A, Wallace P, Ganaway E, Rogers NL, Garvey WT. Troglitazone antagonizes metabolic effects of glucocorticoids in humans. Effects on glucose tolerance, insulin sensitivity, suppression of free fatty acids and leptin.  Diabetes. 2002;  51 2895-2902
    CrossrefPubMedGoogle Scholar
  • 39 Catrina SB, Virtanen K, Hallsten K, Lonnqvist F, Nuutila P, Brismar K. Effect of rosiglitazone on early-morning plasma cortisol levels.  Neuro Endocrinol Lett. 2005;  26 ((1)) 51-54
    PubMedGoogle Scholar
  • 40 Suri D, Weiss RE. Effect of Pioglitazone on ACTH and Cortisol Secretion in Cushing's Disease.  J Clin Endocrin Metal. 2005;  90 ((3)) 1340-1346
    PubMedGoogle Scholar
  • 41 Motomura W, Okumura T, Takahashi N, Obara T, Kohgo Y. Activation of peroxisome proliferator-activated receptor gamma by troglitazone inhibits cell growth through the increase of p27KiP1 in human. Pancreaticcarcinoma cells.  Cancer Res. 2000;  , 1 60 ((19)) 5558-5564
    PubMedGoogle Scholar
  • 42 Sugimura A, Kiriyama Y, Nochi H, Tsuchiya H, Tamoto K, Sakurada Y, Ui M, Tokumitsu Y. Troglitazone suppresses cell growth of myeloid leukemia cell lines by induction of p21WAF1/CIP1 cyclin-dependent kinase inhibitor.  Biochem Biophys Res Commun. 1999;  , 11 261 ((3)) 833-837
    CrossrefPubMedGoogle Scholar
  • 43 Goke R, Goke A, Goke B, Chen Y. Regulation of TRAIL-induced apoptosis by transcription factors.  Cell Immunol. 2000;  201 ((2)) 77-82
    CrossrefPubMedGoogle Scholar
  • 44 Staels B, Koenig W, Habib A, Merval R, Lebret M, Torra IP, Delerive P, Fadel A, Chinetti G, Fruchart JC, Najib J, Maclouf J, Tedgui A. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators.  Nature. 1998;  , 25 393 ((6687)) 790-793
    CrossrefPubMedGoogle Scholar
  • 45 Aktas H, Fluckiger R, Acosta JA, Savage JM, Palakurthi SS, Halperin JA. Depletion of intracellular Ca2+ stores, phosphorylation of eIF2alpha, and sustained inhibition of translation initiation mediate the anticancer effects of clotrimazole.  Proc Natl Acad Sci. 1998;  , 15 95 ((14)) 8280-8285
    CrossrefPubMedGoogle Scholar

Correspondence

M. Morcos

University of Heidelberg

Dept. of Internal Medicine I

Endocrinology and Metabolism and Clinical Chemistry INF 410

69120 Heidelberg

Germany

Phone: +49/62/21/56 38 604

Fax: +49/62/21/56 41 01

Email: Michael_Morcos@med.uniheidelberg.de

      >